Статья

Improving target assessment in biomedical research: the GOT-IT recommendations

C. Emmerich, L. Gamboa, M. Hofmann, M. Bonin-Andresen, O. Arbach, P. Schendel, B. Gerlach, K. Hempel, A. Bespalov, U. Dirnagl, M. Parnham,
2021

Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research must progress from purely academic exploration to the initiation of efforts to identify and test a drug candidate in clinical trials, which are typically conducted by the biopharma industry. This transition can be facilitated by a timely focus on target assessment aspects such as target-related safety issues, druggability and assayability, as well as the potential for target modulation to achieve differentiation from established therapies. Here, we present recommendations from the GOT-IT working group, which have been designed to support academic scientists and funders of translational research in identifying and prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical development programmes. Based on sets of guiding questions for different areas of target assessment, the GOT-IT framework is intended to stimulate academic scientists’ awareness of factors that make translational research more robust and efficient, and to facilitate academia–industry collaboration. © 2020, Springer Nature Limited.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • C. Emmerich
    PAASP GmbH, Heidelberg, Germany
  • L. Gamboa
    Department of Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • M. Hofmann
    QUEST Center for Transforming Biomedical Research, Berlin Institute of Health, Berlin, Germany
  • M. Bonin-Andresen
    Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine & Pharmacology TMP, Frankfurt am Main, Germany
  • O. Arbach
    SPARK–Validation Fund, Berlin Institute of Health, Berlin, Germany
  • P. Schendel
    Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • B. Gerlach
    Valdman Institute of Pharmacology, Pavlov Medical University, St. Petersburg, Russian Federation
  • K. Hempel
    Faculty of Biochemistry, Chemistry & Pharmacy, J.W. Goethe University Frankfurt, Frankfurt am Main, Germany
  • A. Bespalov
  • U. Dirnagl
  • M. Parnham
Название журнала
  • Nature Reviews Drug Discovery
Том
  • 20
Выпуск
  • 1
Страницы
  • 64-81
Ключевые слова
  • awareness; conceptual framework; consensus; data quality; decision making; documentation; drug safety; electronic medical record; evidence based medicine; feasibility study; Food and Drug Administration; funding; health care need; health care organization; health care system; health program; licensing; medical research; patent; pathophysiology; practice guideline; priority journal; process optimization; Review; scientist; tissue distribution; validity; virus cell interaction
Издатель
  • Nature Research
Тип документа
  • Review
Источник
  • scopus